Introduce novelty to your meals The Japanese word Kuchisabishii literally means eating because your mouth is lonely. However, the term really refers to eating when bored
Arthur and Bonnie Ennis Foundation, Decatur, IL, USA
Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK Brain fog does not appear in the MHRA-approved Summary of Product Characteristics as an established adverse effect Potential mechanisms include blood glucose fluctuations, reduced caloric intake, gastrointestinal symptoms affecting nutrition and sleep, or central nervous system effects Management strategies include optimising nutrition and hydration, monitoring glucose levels, prioritising sleep, and following gradual dose titration Patients should seek medical advice for severe, worsening, or persistent cognitive symptoms, or if experiencing signs of hypoglycaemia or dehydration All suspected adverse effects should be reported through the MHRA Yellow Card Scheme to support ongoing pharmacovigilance Table of Contents Understanding Mounjaro and Its Mechanism of Action Brain Fog as a Potential Side Effect: What the Evidence Shows Why Mounjaro Might Contribute to Cognitive Symptoms Managing and Reducing Brain Fog While Taking Mounjaro When to Seek Medical Advice About Cognitive Changes Scientific References Frequently Asked Questions Understanding Mounjaro and Its Mechanism of Action Mounjaro (tirzepatide) is a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus
continued treatment generally required to sustain losses It is essential to emphasise that GLP-1 medications are not a standalone solution
His compassionate approach and expertise in managing these conditions ensure that patients receive the best possible support and guidance
